Method of directed differentiation producing corneal endothelial cells from neural crest stem cells by PDGFB and DKK2, compositions thereof, and uses thereof

Patent metadata

Field	Value
Publication number	US-9752118-B2
Application number	US-201214362775-A
Country	US
Kind code	B2
Filing date	Dec 6, 2012
Priority date	Dec 6, 2011
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.

First claim

The invention claimed is:

1. A method of producing corneal endothelial cells (CECs), comprising
contacting embryonic stem (ES) cells with Noggin and 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide (SB431542) to induce differentiation of the ES cells into neural crest stem cells (NCSCs); and
contacting the NCSCs with dickkopf-related protein 2 (DKK2), and platelet-derived growth factor subunit B (PDGFB), to induce differentiation of the NCSCs into CECs that express Na+/K+ ATPase, ZO-1, KLF13, AQP1, Collagen VIII, SLC16A3, CFTR, NBC1, Carbonic anhydrase II (CA2), Anion exchanger 2 (AE2/SCL4A2), Solute Carrier Family 16 A1 (SCL16A1), SCL16A3, Carbonic anhydrase 12 (CA12), Carbonic Anhydrase 4 (CA4), cystic fibrosis transmembrane conductance regulator (CFTR) and transcription factor FoxC1.

2. The method of claim 1 , wherein the method comprises contacting NCSCs with DKK2 having a concentration of between 2 ng/ml and 20 ng/ml.

3. The method of claim 1 , wherein the method comprises contacting NCSCs with PDGFB having a concentration of between 2 ng/ml and 20 ng/ml.

4. The method of claim 1 , further comprising culturing the CECs on a matrix.

5. The method of claim 4 , wherein the matrix is selected from: laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, collagen VIII, heparan sulfate, a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, a human basement membrane extract, and any combination thereof.

6. The method of claim 4 , wherein the matrix is a soluble preparation obtained from EHS mouse sarcoma cells (MATRIGEL®).

7. The method of claim 1 , wherein the NCSCs express Sox10, AP2, HNK1, Pax3, PAX7 and p75 (NGFR).

8. The method of claim 1 , wherein the CECs do not express vWF and CD31.

9. The method of claim 1 , wherein the ES cells are human ES cells and the CECs are human CECs.

Assignees

• Astellas Inst For Regenerative Medicine

Inventors

• Mccabe Kathryn L
• Lu Shi-Jiang
• Lanza Robert P

Classifications

• A61L27/3839

  characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60) · CPC title

• C12N2501/155

  Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N5/0621 Primary

  Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title